Tags

Type your tag names separated by a space and hit enter

High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Tumour Biol. 2016 Jun; 37(6):7129-37.TB

Abstract

Salient studies have investigated the association between host inflammatory response and cancer. This study was conducted to test the hypothesis that peripheral absolute monocyte counts (AMC) could impart an increased risk of hepatocellular carcinoma (HCC) development in hepatitis C virus (HCV)-infected patients after a failed peginterferon/ribavirin (PR) combination therapy. A total of 723 chronic HCV-infected patients were treated with PR, of which 183 (25.3 %) patients did not achieve a sustained virological response (non-SVR). Post-treatment AMC values were measured at 6 months after end of PR treatment. Fifteen (2.8 %) of 540 patients with an SVR developed HCC during a median follow-up period of 41.4 months, and 14 (7.7 %) of 183 non-SVR patients developed HCC during a median follow-up of 36.8 months (log rank test for SVR vs. non-SVR, P = 0.002). Cox regression analysis revealed that post-treatment AFP level (HR 1.070; 95 % CI = 1.024-1.119, P = 0.003) and post-treatment aspartate aminotransferase (AST)-to-platelet ratio index (APRI) ≥0.5 (HR 4.401; 95 % CI = 1.463-13.233, P = 0.008) were independent variables associated with HCC development for SVR patients. For non-SVR patients, diabetes (HR 5.750; 95 % CI = 1.387-23.841, P = 0.016), post treatment AMC ≥370 mm(-3) (HR 5.805; 95 % CI = 1.268-26.573, P = 0.023), and post-treatment APRI ≥1.5 (HR 10.905; 95 % CI = 2.493-47.697, P = 0.002) were independent risks associated with HCC. In conclusion, post-treatment AMC has a role in prognostication of HCC development in HCV-infected patients who failed to achieve an SVR after PR combination therapy.

Authors+Show Affiliations

Division of Hepato-Gastroenterology, Department of Internal Medicine, Tungs' Taichung Metro Harbor Hospital, No. 699, Sec. 8, Taiwan Blvd, Taichung City, 43503, Taiwan. t4696@ms.sltung.com.tw. Department of Health Food, Chung Chou University of Science and Technology, No. 6, Lane 2, Sec. 3, Shanjiao Rd., Yuanlin Township, Changhua County, 51003, Taiwan. t4696@ms.sltung.com.tw.Institute of Medicine, Chung Shan Medical University, No. 110, Sec 1, Chien-Ko N. Rd, Taichung City, 40201, Taiwan. cshy333@csh.org.tw. Division of Gastroenterology, Department of Internal Medicine, Chung Shan Medical University Hospital, No. 110, Sec 1, Chien-Ko N. Rd, Taichung City, 40201, Taiwan. cshy333@csh.org.tw.Division of Hepato-Gastroenterology, Department of Internal Medicine, Tungs' Taichung Metro Harbor Hospital, No. 699, Sec. 8, Taiwan Blvd, Taichung City, 43503, Taiwan.Department of Medical Research, Tungs' Taichung Metro Harbor Hospital, No. 699, Sec. 8, Taiwan Blvd, Taichung City, 43503, Taiwan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26662957

Citation

Chen, Tsung-Ming, et al. "High Post-treatment Absolute Monocyte Count Predicted Hepatocellular Carcinoma Risk in HCV Patients Who Failed Peginterferon/ribavirin Therapy." Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 37, no. 6, 2016, pp. 7129-37.
Chen TM, Lin CC, Huang PT, et al. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. Tumour Biol. 2016;37(6):7129-37.
Chen, T. M., Lin, C. C., Huang, P. T., & Wen, C. F. (2016). High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 37(6), 7129-37. https://doi.org/10.1007/s13277-015-4593-6
Chen TM, et al. High Post-treatment Absolute Monocyte Count Predicted Hepatocellular Carcinoma Risk in HCV Patients Who Failed Peginterferon/ribavirin Therapy. Tumour Biol. 2016;37(6):7129-37. PubMed PMID: 26662957.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. AU - Chen,Tsung-Ming, AU - Lin,Chun-Che, AU - Huang,Pi-Teh, AU - Wen,Chen-Fan, Y1 - 2015/12/12/ PY - 2015/10/18/received PY - 2015/12/03/accepted PY - 2015/12/15/entrez PY - 2015/12/15/pubmed PY - 2017/2/9/medline KW - Absolute monocyte count KW - Hepatitis C virus KW - Hepatocellular carcinoma KW - Peginterferon SP - 7129 EP - 37 JF - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine JO - Tumour Biol. VL - 37 IS - 6 N2 - Salient studies have investigated the association between host inflammatory response and cancer. This study was conducted to test the hypothesis that peripheral absolute monocyte counts (AMC) could impart an increased risk of hepatocellular carcinoma (HCC) development in hepatitis C virus (HCV)-infected patients after a failed peginterferon/ribavirin (PR) combination therapy. A total of 723 chronic HCV-infected patients were treated with PR, of which 183 (25.3 %) patients did not achieve a sustained virological response (non-SVR). Post-treatment AMC values were measured at 6 months after end of PR treatment. Fifteen (2.8 %) of 540 patients with an SVR developed HCC during a median follow-up period of 41.4 months, and 14 (7.7 %) of 183 non-SVR patients developed HCC during a median follow-up of 36.8 months (log rank test for SVR vs. non-SVR, P = 0.002). Cox regression analysis revealed that post-treatment AFP level (HR 1.070; 95 % CI = 1.024-1.119, P = 0.003) and post-treatment aspartate aminotransferase (AST)-to-platelet ratio index (APRI) ≥0.5 (HR 4.401; 95 % CI = 1.463-13.233, P = 0.008) were independent variables associated with HCC development for SVR patients. For non-SVR patients, diabetes (HR 5.750; 95 % CI = 1.387-23.841, P = 0.016), post treatment AMC ≥370 mm(-3) (HR 5.805; 95 % CI = 1.268-26.573, P = 0.023), and post-treatment APRI ≥1.5 (HR 10.905; 95 % CI = 2.493-47.697, P = 0.002) were independent risks associated with HCC. In conclusion, post-treatment AMC has a role in prognostication of HCC development in HCV-infected patients who failed to achieve an SVR after PR combination therapy. SN - 1423-0380 UR - https://www.unboundmedicine.com/medline/citation/26662957/High_post_treatment_absolute_monocyte_count_predicted_hepatocellular_carcinoma_risk_in_HCV_patients_who_failed_peginterferon/ribavirin_therapy_ L2 - https://link.springer.com/article/10.1007/s13277-015-4593-6 DB - PRIME DP - Unbound Medicine ER -